hyperCORE International

What hyperCORE International does

hyperCORE International is a privately held, partner-owned clinical research site organization (SMO) founded in 2019 and headquartered virtually in the United States. It operates as a federated super network of independent clinical research site companies — currently 70+ active research sites across 5 countries and 2 continents (North and South America: USA, Canada, Peru, Brazil, Argentina) — providing Phase I-IV clinical trial execution services to pharmaceutical sponsors and Contract Research Organizations (CROs). The organization differentiates through a centralized contracting and single-budget model, harmonized SOPs across member sites, and a single point of contact for sponsors engaging the full network. Its Phase 1 capabilities include 9 sites in 14 locations with 23 Principal Investigators, 131 overnight beds, and on-site pharmacies.

The network's technology stack is virtual-first and digitally connected: all sites are Virtual Trial Certified via a partnership with VirTrial, enabling hybrid and decentralized clinical trials through telehealth, remote patient monitoring, and mobile units (including FOMAT's clinical research ambulance). hyperCORE has completed over 7,000 studies and randomized more than 140,000 patients, with five partner sites named Top 20 Enrollers in Pfizer's landmark COVID-19 vaccine study (~10% of global vaccine study patients) and a 90% diversity score on the SCRS Diversity Site Assessment Tool. Revenue is generated through per-study professional services fees negotiated with sponsors and CROs; specific pricing, contract values, and financial performance are not publicly disclosed. The company is led by CEO Karri Venn (appointed October 2020) with Nicholas Focil as President, and operates with a partner-ownership structure — no PE, VC, or institutional investor backing is disclosed.

Go-to-market is enterprise field sales driven, with conference presence (SCRS, SCOPE, ACRP, DIA, BIO, World Vaccine Congress), earned media, and direct executive-level relationships with pharmaceutical and CRO buyers. The network pursues growth by vetting and onboarding new partner site organizations rather than through M&A or external capital deployment, and has been recognized as one of the top six global site networks invited to a 2025 strategic industry advisory group.

Name

hyperCORE International

Legal name

hyperCORE International

Website

https://hypercoreinternational.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

101–250 employees

Short description

hyperCORE International is a partner-owned super network of 70+ independent clinical research sites across North and South America, providing Phase I-IV clinical trial services to pharmaceutical sponsors and CROs via centralized contracting, harmonized operations, and virtual trial capabilities.

Ownership category

akta.pro rank

Headquarters

HQ city

Lake Mary

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Clinical Trial Site Services: hyperCORE International generates revenue by providing clinical trial site services to pharmaceutical sponsors and CROs. The network charges fees for conducting Phase I-IV clinical trials across its partner site network, with centralized contracting and billing. Revenue is derived from study execution fees, enrollment performance, and pass-through costs from its network of independent partner sites operating under unified operational frameworks.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

hyperCORE International is a partner-owned super network of independent clinical research site companies providing Phase I-IV clinical trial execution services to pharmaceutical sponsors and CROs. The network spans 70+ active research sites across 2 continents and 5 countries, offering sponsors a single point of contact, centralized contracts and budgets, harmonized SOPs, and decentralized/hybrid trial capabilities. It is the second-largest clinical research site organization globally.

Product overview

hyperCORE International is a partner site network (Site Management Organization) composed of highly experienced and awarded independent clinical research companies working together as a super network. The organization provides Phase I-IV clinical trial services through its network of 70+ active research sites across North and South America. Key offerings include decentralized clinical trial (DCT) services with virtual trial capabilities, specialized Phase 1 therapeutic services with overnight facilities, and comprehensive patient recruitment services. The network operates with harmonized operational frameworks, offering sponsors a single point of contact, centralized contracts and budgets, and streamlined efficiencies for rapid study start-up and execution.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Site Network Services A super network of 70+ highly experienced clinical research site companies providing centralized contracting, single budget, harmonized SOPs, and a unified point of contact across North and South America for pharmaceutical sponsors and CROs.
• Phase I-IV Clinical Trial Services Comprehensive clinical trial execution services spanning all phases of drug and device development, with expertise in oncology, cardio-metabolic, CNS, dermatology, infectious disease, and vaccine research conducted across the partner site network.
• Decentralized Clinical Trial (DCT) Services Direct-to-patient clinical research services enabling remote and hybrid trial participation through virtual visits, remote and mobile units, and telehealth capabilities across the entire hyperCORE network.
• Patient Recruitment Services Expert patient recruitment leveraging diverse patient populations across therapeutic areas, with demonstrated high enrollment performance and access to over 1 million potential patients across North and South America.
• Phase 1 Therapeutics Services Specialized Phase 1 clinical trial services including first-in-human studies, overnight dosing facilities (131 beds across 8 locations), on-site pharmacies at 6 sites, and PBMC processing at 5 sites, supported by 23 Principal Investigators.

Quantifiable outcome

• Second-largest clinical research site organization in the world with 70+ sites across 2 continents and 5 countries
• +5 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core, key and minor.

• VirTrialcoreTechnology or Integration · 16 September 2019VirTrial partnered with hyperCORE International to provide virtual trial technology across the entire network. hyperCORE became the first site network to have all sites trained and certified as Virtual Trial Capable. VirTrial's telehealth platform enables hybrid decentralized clinical trials through video, text, and email, allowing sponsors to replace some in-person visits with virtual visits.
• ParexelkeyStrategic or Co-development PartnerhyperCORE and Parexel formed a site alliance network and KOL engagement partnership. Parexel is featured as a partner logo on hyperCORE's website, indicating a strategic working relationship for clinical trial delivery.
• Society for Clinical Research Sites (SCRS) - Environmental Sustainability SAGcoreStrategic or Co-development PartnerhyperCORE is a charter member of the SCRS Environmental Sustainability Site Advocacy Group, contributing to industry-wide initiatives that shape environmental sustainability standards for clinical research sites.
• VaxCorpscoreStrategic or Co-development PartnerhyperCORE is a proud member of VaxCorps, a collaboration of leading clinical research site networks specializing in vaccine research and immunotherapies. The network exhibits at VaxCorps events and leverages this partnership for vaccine trial business development.
• EMS HealthcareminorStrategic or Co-development PartnerEMS Healthcare was honored as the first-ever recipient of the Environmental Sustainability Impact Award at the SCRS Global Site Solutions Summit, an initiative supported by hyperCORE as a charter member of the SCRS Environmental Sustainability SAG.
• Society for Clinical Research Sites (SCRS) - DSATcoreStrategic or Co-development PartnerhyperCORE participated in the development and adoption of the Diversity Site Assessment Tool (DSAT) developed by SCRS, scoring 90% globally and promoting diversity benchmarking across the clinical research site industry.

Scale indicators17 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• IQVIA: IQVIA is the world's largest clinical research services organization, operating a global site network alongside its broader CRO and real-world data businesses. It competes with hyperCORE for sponsor site-selection decisions and dwarfs the field in scale, technology, and geographic reach.
• ICON plc: ICON is a top-3 global CRO with significant site services and decentralized trial capabilities following its acquisition of PRA Health Sciences. It competes with hyperCORE on Phase I-IV trial execution and has a much broader global footprint and capital base.
• Syneos Health: Syneos is a leading biopharmaceutical solutions organization offering both CRO and commercial services, with site network and decentralized trial capabilities. It is a relevant competitor for sponsor trial execution contracts that hyperCORE also pursues.
• Medpace: Medpace is a mid-to-large global CRO with strong mid-sized sponsor relationships and integrated clinical operations. While not site-network-centric like hyperCORE, it competes for many of the same Phase II-IV trial mandates.

Direct peers

• Centricity Research: Centricity Research (formerly LMC Manna Research, a hyperCORE founding partner that departed) is one of North America's largest fully integrated research networks with 40+ sites and 1.5M+ patient access. It is the most directly comparable independent SMO competitor.
• M3 Wake Research: M3 Wake Research is a large multi-therapeutic clinical research site network operating across the US. It directly competes with hyperCORE for sponsor site-selection and offers comparable Phase I-IV capabilities and geographic coverage.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a global mid-size CRO with strong site relationships and therapeutic expertise across Phase I-IV. It competes with hyperCORE for sponsor trial mandates, particularly in complex and specialty therapeutic areas.
• Caidya: Caidya is a global clinical research organization offering full-service CRO capabilities including site management and patient recruitment. It is a comparable peer for sponsor trial execution, particularly for biotech customers.

Emerging players

• Flourish Research: Flourish Research is an emerging SMO roll-up backed by Genstar Capital, formed through the combination of multiple high-performing research sites. It is a direct competitor in the US site network space and signals PE capital flowing into the model hyperCORE pioneered.
• Vial: Vial is a technology-enabled CRO/SMO hybrid building next-generation clinical trial operations. While smaller and earlier stage, its tech-first model represents an emerging competitive vector that could disrupt traditional SMO economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hypercore-international
• Xx.com/hypercoreintl
• Facebookfacebook.com/hypercoreinternational

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about hyperCORE International